Concepedia

Kevin Booth

KB

9

Publications

667

Citations

9

H-Index

1967

Active since

Affiliations

Janssen (United States)(Current)

Pfizer (United States)

Pfizer (France)

Janssen (Belgium)

Pfizer (United Kingdom)

Kevin Booth is an author at Janssen (United States) specializing in medicine, apoptosis, and neurodegenerative diseases.

Top concepts

Publications per year

1967–2018

9

Publications

9

Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

Rik Vandenberghe, Juha O. Rinne, Merçé Boada et al. · Alzheimer s Research & Therapy · 2016 · 293 citations · Full text

Amyloid-β <sup>11</sup> C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

Enchi Liu, Mark E. Schmidt, Richard Margolin et al. · Neurology · 2015 · 149 citations · Full text

Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer’s Disease

Michael Hüll, Carl Sadowsky, Heii Arai et al. · Current Alzheimer Research · 2017 · 60 citations · Full text

Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies

Adrian Ivanoiu, Jérémie Pariente, Kevin Booth et al. · Alzheimer s Research & Therapy · 2016 · 36 citations · Full text

Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab

Enchi Liu, Dai Wang, Reisa A. Sperling et al. · Neurology · 2018 · 36 citations

Rows per page

1–5 of 9